FAKTOR OPTIONSSCHEIN - ELI LILLY & CO | Delayed Deutsche Boerse AG 08:57:39 10/06/2024 pm IST | ||
| 2.94 EUR | -1.01% |
|
| Current month | -13.16% | ||
| 1 month | -25.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 10/24/10 | 2.94 | -1.01% |
| 07/24/07 | 2.97 | -5.71% |
| 06/24/06 | 3.15 | -0.63% |
| 05/24/05 | 3.17 | -1.55% |
| 04/24/04 | 3.22 | -0.62% |
Delayed Quote Deutsche Boerse AG
Last update June 10, 2024 at 08:57 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| WKN | UM2B2J |
| ISIN | DE000UM2B2J1 |
| Date issued | 16/02/2024 |
| Strike | 1,133 $ |
| Maturity | Unlimited |
| Parity | 86.15 : 1 |
| Emission price | 4.88 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.28 € |
|---|---|
| Lowest since issue | 2.9 € |
| Spread | 0.07 € |
| Spread % | 2.33% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
850
USD
Average target price
853.8
USD
Spread / Average Target
+0.44%
- Stock Market
- Certificates
- Certificat
